Home / Market News / $SNDX
benzinga Corporate Catalyst Impact 95/100 ● negative

Syndax Pharmaceuticals shares are trading lower after the company announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint of the annualized rate of decline in forced vital capacity.

Oct 13, 2026, 3:38 PM UTC · Primary ticker $SNDX

Syndax Pharmaceuticals shares are plummeting due to the failure of a key Phase 2 clinical trial for axatilimab. This negative outcome significantly impacts the company's future revenue prospects and pipeline value, leading to a sharp decline in investor confidence.

The failure of a Phase 2 clinical trial for a drug targeting a significant indication like idiopathic pulmonary fibrosis (IPF) is a major corporate catalyst for a biotechnology company. This directly impacts Syndax Pharmaceuticals' valuation, as a substantial portion of its future revenue potential was tied to the success of axatilimab. Investors will likely re-evaluate the company's entire pipeline and risk profile, leading to a sustained negative sentiment. This event also highlights the inherent risks in drug development within the biotechnology sector, where clinical trial outcomes are paramount to stock performance. Other companies developing treatments for IPF might see some indirect impact, either positive if their trials are progressing well, or negative if this failure casts a shadow on the overall difficulty of treating the disease.

$SNDX negative Primary subject of failed clinical trial
$PULM neutral Competitor in IPF treatment, potential indirect impact
$BMY neutral Large pharma with potential interest in IPF, indirect read-through
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.